Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.50 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.45 |
| ▸ | FDPS | P14324 | 2/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7648048 | 0.87 | CYP1A2 (0.42) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL5140906 | 0.76 | GABBR2 (0.56) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL6351937 | 0.76 | GABBR2 (0.50) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL6360302 | 0.74 | GABBR2 (0.54) | LMNABLMCYP3A4NFKB1PMP22 | |
| Hydrochloric Acid SCHEMBL9417053 | 0.74 | GABBR2 (0.48) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL10586239 | 0.71 | GABBR2 (0.55) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL6355094 | 0.71 | GABBR2 (0.55) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL35883 | 0.71 | — | — | |
| SCHEMBL9336332 | 0.70 | GABBR2 (0.48) | LMNABLMCYP3A4NFKB1PMP22 | |
| Phosphoric Acid SCHEMBL7888623 | 0.69 | LMNA (0.94) | LMNABLMCYP3A4NFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002100871-A1 | NEW COMPOUNDS USEFUL IN REFLUX DISEASE | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | WO | claimed |
| US-5567840-A | AS 4-AMINOBUTYRIC ACID AGONIST; MUSCLE RELAXANTS | CIBA-GEIGY CORPORATION (US) | 1996-10-22 | — | — | US | claimed |
| EP-0399949-B1 | Substituted aminoalkylphosphinic acids | CIBA GEIGY AG (CH) | 1995-04-12 | — | — | EP | claimed |
| EP-0399949-A1 | Substituted aminoalkylphosphinic acids | CIBA-GEIGY AG (CH) | 1990-11-28 | — | — | EP | claimed |
| WO-2002100871-A1 | NEW COMPOUNDS USEFUL IN REFLUX DISEASE | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | WO | disclosed |
| US-5567840-A | AS 4-AMINOBUTYRIC ACID AGONIST; MUSCLE RELAXANTS | CIBA-GEIGY CORPORATION (US) | 1996-10-22 | — | — | US | disclosed |
| US-5461040-A | Therapy of spinal spacticity, multiple sclerosis, cerebral palsy, trigeminus neuralgia, drug withdrawal, pain | CIBA-GEIGY CORPORATION (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0399949-B1 | Substituted aminoalkylphosphinic acids | CIBA GEIGY AG (CH) | 1995-04-12 | — | — | EP | disclosed |
| US-5281747-A | Pharmaceuticals | CIBA-GEIGY CORPORATION (US) | 1994-01-25 | — | — | US | disclosed |
| EP-0399949-A1 | Substituted aminoalkylphosphinic acids | CIBA-GEIGY AG (CH) | 1990-11-28 | — | — | EP | disclosed |